Literature DB >> 3436299

Japanese Graves' disease: association with HLA-Bw46.

S Naito1, H Sasaki, K Arakawa.   

Abstract

HLA-A, -B, and -C antigen frequency of 61 Japanese patients with Graves' disease, and HLA-DR and -DQ frequency of 53 patients with it were compared that of 1,998 controls. The prevalence of Bw46 was significantly higher in patients with Graves' disease (23.0% vs 8.4%, Pc less than 0.003). The result was quite different from previous reports on Japanese Graves' disease.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3436299     DOI: 10.1507/endocrj1954.34.685

Source DB:  PubMed          Journal:  Endocrinol Jpn        ISSN: 0013-7219


  4 in total

1.  The inter-locus recombinant HLA-B*4601 has high selectivity in peptide binding and functions characteristic of HLA-C.

Authors:  L D Barber; L Percival; N M Valiante; L Chen; C Lee; J E Gumperz; J H Phillips; L L Lanier; J C Bigge; R B Parekh; P Parham
Journal:  J Exp Med       Date:  1996-08-01       Impact factor: 14.307

2.  Actual Associations between HLA Haplotype and Graves' Disease Development.

Authors:  Katarzyna Zawadzka-Starczewska; Bogusław Tymoniuk; Bartłomiej Stasiak; Andrzej Lewiński; Magdalena Stasiak
Journal:  J Clin Med       Date:  2022-04-29       Impact factor: 4.964

3.  Association between HLA-B*46 allele and Graves disease in Asian populations: a meta-analysis.

Authors:  Yiping Li; Yufeng Yao; Man Yang; Li Shi; Xianli Li; Ying Yang; Ying Zhang; Chunjie Xiao
Journal:  Int J Med Sci       Date:  2013-01-03       Impact factor: 3.738

4.  The Intergenic Recombinant HLA-B∗46:01 Has a Distinctive Peptidome that Includes KIR2DL3 Ligands.

Authors:  Hugo G Hilton; Curtis P McMurtrey; Alex S Han; Zakia Djaoud; Lisbeth A Guethlein; Jeroen H Blokhuis; Jason L Pugh; Ana Goyos; Amir Horowitz; Rico Buchli; Ken W Jackson; Wilfred Bardet; David A Bushnell; Philip J Robinson; Juan L Mendoza; Michael E Birnbaum; Morten Nielsen; K Christopher Garcia; William H Hildebrand; Peter Parham
Journal:  Cell Rep       Date:  2017-05-16       Impact factor: 9.423

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.